Gossamer Bio Inc (NAS:GOSS)
$ 0.6833 -0.0107 (-1.54%) Market Cap: 154.57 Mil Enterprise Value: 121.66 Mil PE Ratio: 0 PB Ratio: 5.69 GF Score: 38/100

Gossamer Bio Inc at Barclays Global Healthcare Conference Transcript

Mar 16, 2022 / 08:20PM GMT
Release Date Price: $8.59 (+1.78%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Good afternoon. Welcome to the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. I am pleased to welcome Gossamer Bio to the stage.

Gossamer has got a catalyst-filled 2022 with a UC readout coming up in the not-too-distant future, and some PAH data potentially in the back half of the year. We've got a number of people from the company today.

We've got Bryan Giraudo, COO, CFO. You've got another title every other quarter. Richard Aranda, CMO; and Robert Roscigno, who runs the PAH program. Guys, thank you very much for joining us today.

Bryan Giraudo
Gossamer Bio, Inc. - COO & CFO

Thank you for having us, Carter. And thanks to the Barclays organization. Great to be back in person.

Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Maybe before we get started, Bryan, I might just ask you to make just a couple of opening comments around the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot